103 related articles for article (PubMed ID: 32942305)
81. Human aortic endothelial cell labeling with positive contrast gadolinium oxide nanoparticles for cellular magnetic resonance imaging at 7 Tesla.
Loai Y; Sakib N; Janik R; Foltz WD; Cheng HL
Mol Imaging; 2012 Apr; 11(2):166-75. PubMed ID: 22469244
[TBL] [Abstract][Full Text] [Related]
82. Determination of radiosensitivity in established and primary squamous cell carcinoma cultures using the micronucleus assay.
Champion AR; Hanson JA; Venables SE; McGregor AD; Gaffney CC
Eur J Cancer; 1997 Mar; 33(3):453-62. PubMed ID: 9155532
[TBL] [Abstract][Full Text] [Related]
83. Relationships between DNA damage and the survival of radiosensitive mutant Chinese hamster cell lines exposed to gamma-radiation. Part 1: Intrinsic radiosensitivity.
Green A; Prager A; Stoudt PM; Murray D
Int J Radiat Biol; 1992 Apr; 61(4):465-72. PubMed ID: 1349328
[TBL] [Abstract][Full Text] [Related]
84. Radiobiological Implications of Nanoparticles Following Radiation Treatment.
Ahmad R; Schettino G; Royle G; Barry M; Pankhurst QA; Tillement O; Russell B; Ricketts K
Part Part Syst Charact; 2020 Apr; 37(4):1900411. PubMed ID: 34526737
[TBL] [Abstract][Full Text] [Related]
85. Gadolinium retention effect on macrophages - a potential cause of MRI contrast agent Dotarem toxicity.
Halasa M; Uosef A; Ubelaker HV; Subuddhi A; Mysore KR; Kubiak JZ; Ghobrial RM; Wosik J; Kloc M
Cell Tissue Res; 2024 Jul; 397(1):51-60. PubMed ID: 38625373
[TBL] [Abstract][Full Text] [Related]
86. Feasibility of cardiac-synchronized quantitative T
Akdag O; Mandija S; van Lier ALHMW; Borman PTS; Schakel T; Alberts E; van der Heide O; Hassink RJ; Verhoeff JJC; Mohamed Hoesein FAA; Raaymakers BW; Fast MF
Phys Imaging Radiat Oncol; 2022 Jan; 21():153-159. PubMed ID: 35287380
[TBL] [Abstract][Full Text] [Related]
87. The Effect of Magnetic Field Gradient and Gadolinium-Based MRI Contrast Agent Dotarem on Mouse Macrophages.
Chanana P; Uosef A; Vaughn N; Suarez-Villagran M; Ghobrial RM; Kloc M; Wosik J
Cells; 2022 Feb; 11(5):. PubMed ID: 35269379
[TBL] [Abstract][Full Text] [Related]
88. Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation.
Williams JR; Zhang Y; Zhou H; Gridley DS; Koch CJ; Slater JM; Little JB
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):909-17. PubMed ID: 19014780
[TBL] [Abstract][Full Text] [Related]
89. Effects of Gadolinium MRI Contrast Agents on DNA Damage and Cell Survival when Used in Combination with Radiation.
Russell E; McMahon SJ; Russell B; Mohamud H; McGarry CK; Schettino G; Prise KM
Radiat Res; 2020 Sep; 194(3):298-309. PubMed ID: 32942305
[TBL] [Abstract][Full Text] [Related]
90. Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assay.
Donnelly ET; Liu Y; Paul TK; Rockwell S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1176-86. PubMed ID: 15990023
[TBL] [Abstract][Full Text] [Related]
91. Enhanced cytotoxic and genotoxic effects of gadolinium-doped ZnO nanoparticles on irradiated lung cancer cells at megavoltage radiation energies.
Zangeneh M; Nedaei HA; Mozdarani H; Mahmoudzadeh A; Salimi M
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109739. PubMed ID: 31349426
[TBL] [Abstract][Full Text] [Related]
92. The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry.
Brekke C; Morgan SC; Lowe AS; Meade TJ; Price J; Williams SC; Modo M
NMR Biomed; 2007 Apr; 20(2):77-89. PubMed ID: 16952123
[TBL] [Abstract][Full Text] [Related]
93. Impact of superparamagnetic iron oxide nanoparticles on in vitro and in vivo radiosensitisation of cancer cells.
Russell E; Dunne V; Russell B; Mohamud H; Ghita M; McMahon SJ; Butterworth KT; Schettino G; McGarry CK; Prise KM
Radiat Oncol; 2021 Jun; 16(1):104. PubMed ID: 34118963
[TBL] [Abstract][Full Text] [Related]
94. Relationships between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines.
Eastham AM; Atkinson J; West CM
Int J Radiat Biol; 2001 Mar; 77(3):295-302. PubMed ID: 11258843
[TBL] [Abstract][Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
